The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 24, 2020
Filed:
Oct. 09, 2015
Applicant:
Research Institute AT Nationwide Children's Hospital, Columbus, OH (US);
Inventors:
Jerry R. Mendell, Columbus, OH (US);
Brian K. Kaspar, Westerville, OH (US);
Samiah Al-Zaidy, Columbus, OH (US);
Assignee:
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, Columbus, OH (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 39/23 (2006.01); C12N 15/86 (2006.01); C07H 21/04 (2006.01); A61K 38/17 (2006.01); C07K 14/47 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0075 (2013.01); A61K 38/1709 (2013.01); A61K 48/00 (2013.01); C07K 14/4703 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C07H 21/04 (2013.01); C12N 2750/14142 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01); C12N 2799/025 (2013.01);
Abstract
The disclosure relates to methods for treating subjects with musculoskeletal diseases or with muscle wasting not associated with a musculoskeletal disease by gene transfer with recombinant adeno-associated viruses (rAAV) encoding myostatin inhibitors such as follistatin-344. The rAAV are administered prior to development of diffuse muscle fibrosis in a subject, or the rAAV administration avoids regions of muscle fibrosis in a subject.